ONCOLOGY DEVELOPMENT PIPELINE

Novel therapies, new mechanisms

Pfizer Oncology is committed to discovering, investigating, and developing transformative therapies that improve the outlook for cancer patients worldwide.

Our strong pipeline—one of the most robust in the industry—includes biologics, small molecules, immunotherapies, and biosimilars, and is centered on exploring a wide array of approaches across many tumor types. We seek to translate the most innovative science into meaningful breakthrough medicines that redefine life with cancer for patients.

 

Oncology Pipeline & Trials

Oncology Pipeline as of April 28, 2020

  • Discovery Projects
  • Phase 1
    14
  • Phase 2
    10
  • Phase 3
    10
  • Registration
    5
  • Total39
Submission Type
Compound Type
Phase of Development
Compound NameIndicationPhaseSubmission TypeCompound Type
Braftovi (encorafinib) + Erbitux®(cetuximab)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
BRAF kinased inhibitor
Go to clinical trial
2nd or 3rd Line BRAF-mutant Metastatic Colorectal Cancer (E.U.) Registration Product Enhancement Small Molecule
Daurismo (glasdegib)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
SMO (smoothened) antagonist
Combo w/low-dose cytarabine (LDAC) for Acute Myeloid Leukemia (E.U.) Registration New Molecular Entity Small Molecule
PF-06881894, a potential biosimilar to Neulasta® (Pegfilgrastim)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Biosimilar
Business Segment:
Biopharma
Mechanism of Action:
Human Granulocyte Colony Stimulating Factor
Neutropenia in patients undergoing cancer chemotherapy (Biosimilar) (U.S., E.U.) Registration Biosimilar Biosimilar
Xtandi (enzalutamide)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
Androgen receptor inhibitor
Metastatic Hormone Sensitive Prostate Cancer (E.U.) Registration Product Enhancement Small Molecule
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
1st Line Urothelial Cancer (Biologic) (BREAKTHROUGH - U.S)
Project advanced
Registration Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
1st Line Non-Small Cell Lung Cancer (Biologic) Phase 3 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
1st Line Urothelial Cancer (Biologic) Phase 3 Product Enhancement Biologic
Daurismo (glasdegib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
SMO (smoothened) antagonist
Go to clinical trial
Combo w/azacytidine in Acute Myeloid Leukemia (ORPHAN - U.S., E.U.) Phase 3 Product Enhancement Small Molecule
Ibrance (palbociclib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
CDK 4,6 Kinase Inhibitor
Go to clinical trial
High Risk Early Breast Cancer Phase 3 Product Enhancement Small Molecule
Ibrance (palbociclib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
CDK 4,6 Kinase Inhibitor
Go to clinical trial
Early Breast Cancer in Adjuvant Setting Phase 3 Product Enhancement Small Molecule
Ibrance (palbociclib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
CDK 4,6 Kinase Inhibitor
Go to clinical trial
ER+/HER2+ Breast Cancer Phase 3 Product Enhancement Small Molecule
Lorbrena (lorlatinib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
ALK Inhibitor
Go to clinical trial
1st Line ALK Non-Small Cell Lung Cancer (ORPHAN - U.S.) Phase 3 Product Enhancement Small Molecule
PF-06801591 + Bacillus Calmette-Guerin (BCG)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
Anti-PD-1
Go to clinical trial
Non-Muscle-Invasive Bladder Cancer (Biologic) Phase 3 New Molecular Entity Biologic
Talzenna (talazoparib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
PARP inhibitor
Go to clinical trial
Combo w/ Xtandi (enzalutamide) for 1st Line Metastatic Castration-Resistant Prostate Cancer Phase 3 Product Enhancement Small Molecule
Xtandi (enzalutamide)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
Androgen receptor inhibitor
Go to clinical trial
Non-metastatic High Risk Hormone Sensitive Prostate Cancer Phase 3 Product Enhancement Small Molecule
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
1st Line Merkel Cell Carcinoma (Biologic) Phase 2 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Combo w/Talzenna (talazoparib) for Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors (Biologic) Phase 2 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Combo w/Talzenna (talazoparib) for Solid Tumors with a BRCA or ATM defect (Biologic) Phase 2 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Combo w/CMP-001 for Head and Neck Cancer Phase 2 Product Enhancement Biologic
Braftovi (encorafinib) + Mektovi (binimetinib)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
BRAF kinased inhibitor and MEK inhibitor
BRAF-mutant Metastatic Melanoma (ORPHAN - U.S.) Phase 2 Product Enhancement Small Molecule
Braftovi (encorafinib) + Mektovi (binimetinib)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
BRAF kinased inhibitor and MEK inhibitor
1st Line BRAF-mutant Colorectal Cancer Phase 2 Product Enhancement Small Molecule
Braftovi (encorafinib) + Mektovi (binimetinib)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
BRAF kinased inhibitor and MEK inhibitor
1st Line BRAF-mutant Non-Small Cell Lung Cancer Phase 2 Product Enhancement Small Molecule
Daurismo (glasdegib)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
SMO (smoothened) antagonist
Myelodysplastic Syndrome Phase 2 Product Enhancement Small Molecule
Talzenna (talazoparib)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
PARP inhibitor
2nd Line Metastatic Castration-Resistant Prostate Cancer Phase 2 Product Enhancement Small Molecule
Talzenna (talazoparib)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
PARP inhibitor
Germline BRCA Mutated Locally Advanced Triple Negative Breast Cancer Phase 2 Product Enhancement Small Molecule
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Combo w/ Talzenna (talazoparib) and binimetinib for Solid Tumors (Biologic) Phase 1 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Cancer (Biologic) Phase 1 Product Enhancement Biologic
PF-05082566
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
CD137 Agonist
Combo w/Kite Pharma'sYescarta (axicabtagene ciloleucel)forCancer Phase 1 New Molecular Entity Biologic
PF-06647020
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
protein tyrosine kinase 7 (PTK7) Targeted Cytotoxicity
Cancer (Biologic) Phase 1 New Molecular Entity Biologic
PF-06753512
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Therapeutic Vaccine
Prostate Cancer Phase 1 New Molecular Entity Vaccine
PF-06804103
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
HER2 Antibody Drug Conjugate
Cancer (Biologic) Phase 1 New Molecular Entity Biologic
PF-06821497
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
EZH2 inhibitor
Cancer Phase 1 New Molecular Entity Small Molecule
PF-06863135
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
BCMA-CD3 Bispecific Antibody
Multiple Myeloma (Biologic) Phase 1 New Molecular Entity Biologic
PF-06873600
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
CDK 2,4,6 inhibitor
Breast Cancer Metastatic Phase 1 New Molecular Entity Small Molecule
PF-06936308
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Therapeutic Vaccine
Multiple Cancers Phase 1 New Molecular Entity Vaccine
PF-06939999
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
protein arginine methyltransferase 5 (PRMT5) Inhibitor
Solid Tumors Phase 1 New Molecular Entity Small Molecule
PF-06940434
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
Integrin alpha-V/beta-8 Antagonist
Solid Tumors (Biologic) Phase 1 New Molecular Entity Biologic
PF-06952229
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
transforming growth factor, beta receptor 1 (TGFBR1) Inhibitor
Cancer Phase 1 New Molecular Entity Small Molecule
PF-07062119
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
GUCY2c CD3 Bispecific Antibody
Solid Tumors (Biologic) Phase 1 New Molecular Entity Biologic